Tratamento do carcinoma metastático
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614 http://hdl.handle.net/11449/67702 |
Resumo: | The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC). |
id |
UNSP_6104117786d884ad1413c744f1a24ede |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/67702 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Tratamento do carcinoma metastáticoTreatment of the metastatic renal cell carcinomaImunotherapyMetastasisRenal cell carcinomaTreatmentalpha interferoninterleukin 2age distributioncancer chemotherapycancer combination chemotherapycancer hormone therapycancer immunotherapycancer incidencecancer radiotherapycancer survivalclinical trialechographyhumanimagingincidental findingkidney carcinomametastasisnephrectomyreviewsex differenceUnited StatesThe renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC).Departamento de Oncologia Instituto de Urologia e Nefrologia, São José do Rio PretoInstituto de Urologia e Nefrologia, São José do Rio PretoFaculdade de Medicina de BotucatuInstituto de Urologia e Nefrologia, Rua Voluntários de Sao Paulo, Sao Jose do Rio Preto - SPFaculdade de Medicina de BotucatuInstituto de Urologia e NefrologiaUniversidade Estadual Paulista (Unesp)Verona, Carlos BeneditoZerati Filho, Miguel [UNESP]El Ammar Müller, MárcioAlmeida Calado, Adriano2014-05-27T11:21:04Z2014-05-27T11:21:04Z2004-04-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article222-227http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614Revista Brasileira de Medicina, v. 61, n. 4, p. 222-227, 2004.0034-7264http://hdl.handle.net/11449/677022-s2.0-2942527338Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPporRevista Brasileira de Medicina0,101info:eu-repo/semantics/openAccess2021-10-22T20:03:59Zoai:repositorio.unesp.br:11449/67702Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T20:18:51.980397Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Tratamento do carcinoma metastático Treatment of the metastatic renal cell carcinoma |
title |
Tratamento do carcinoma metastático |
spellingShingle |
Tratamento do carcinoma metastático Verona, Carlos Benedito Imunotherapy Metastasis Renal cell carcinoma Treatment alpha interferon interleukin 2 age distribution cancer chemotherapy cancer combination chemotherapy cancer hormone therapy cancer immunotherapy cancer incidence cancer radiotherapy cancer survival clinical trial echography human imaging incidental finding kidney carcinoma metastasis nephrectomy review sex difference United States |
title_short |
Tratamento do carcinoma metastático |
title_full |
Tratamento do carcinoma metastático |
title_fullStr |
Tratamento do carcinoma metastático |
title_full_unstemmed |
Tratamento do carcinoma metastático |
title_sort |
Tratamento do carcinoma metastático |
author |
Verona, Carlos Benedito |
author_facet |
Verona, Carlos Benedito Zerati Filho, Miguel [UNESP] El Ammar Müller, Márcio Almeida Calado, Adriano |
author_role |
author |
author2 |
Zerati Filho, Miguel [UNESP] El Ammar Müller, Márcio Almeida Calado, Adriano |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Instituto de Urologia e Nefrologia Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Verona, Carlos Benedito Zerati Filho, Miguel [UNESP] El Ammar Müller, Márcio Almeida Calado, Adriano |
dc.subject.por.fl_str_mv |
Imunotherapy Metastasis Renal cell carcinoma Treatment alpha interferon interleukin 2 age distribution cancer chemotherapy cancer combination chemotherapy cancer hormone therapy cancer immunotherapy cancer incidence cancer radiotherapy cancer survival clinical trial echography human imaging incidental finding kidney carcinoma metastasis nephrectomy review sex difference United States |
topic |
Imunotherapy Metastasis Renal cell carcinoma Treatment alpha interferon interleukin 2 age distribution cancer chemotherapy cancer combination chemotherapy cancer hormone therapy cancer immunotherapy cancer incidence cancer radiotherapy cancer survival clinical trial echography human imaging incidental finding kidney carcinoma metastasis nephrectomy review sex difference United States |
description |
The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC). |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-04-01 2014-05-27T11:21:04Z 2014-05-27T11:21:04Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614 Revista Brasileira de Medicina, v. 61, n. 4, p. 222-227, 2004. 0034-7264 http://hdl.handle.net/11449/67702 2-s2.0-2942527338 |
url |
http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614 http://hdl.handle.net/11449/67702 |
identifier_str_mv |
Revista Brasileira de Medicina, v. 61, n. 4, p. 222-227, 2004. 0034-7264 2-s2.0-2942527338 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Revista Brasileira de Medicina 0,101 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
222-227 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129187334062080 |